A- A A+

The impact of the COVID-19 pandemic on access to supervised consumption programs. 

Gubskaya E, Kennedy MC, Hayashi K, Cui Z, Milloy MJ, Kerr T. 

Subst Abuse Treat Prev Policy. 2023 Mar 10;18(1):16. doi: 10.1186/s13011-023-00521-6. PMID: 36899417; PMCID: PMC9999333.


Factors associated with receptive injection equipment sharing among people who inject drugs: findings from a multistate study at the start of the COVID-19 pandemic. 

Allen ST, Schneider KE, Morris M, Rouhani S, Harris SJ, Saloner B, Sherman SG. 

Harm Reduct J. 2023 Feb 15;20(1):18. doi: 10.1186/s12954-023-00746-5. PMID: 36793041; PMCID: PMC9930060.


Using formative evaluation of a community-based opioid overdose prevention program to inform strategic communication for adoption, implementation, and sustainability. 

Bangham C, Cunnington S, Fielman S, Hurley M, Gergerian S, Greece JA. 

BMC Public Health. 2023 Feb 15;23(1):341. doi: 10.1186/s12889-023-15229-2. PMID: 36793001; PMCID: PMC9930042.


Network-level HIV risk norms are associated with individual-level HIV risk and harm reduction behaviors among people who inject drugs: a latent profile analysis. 

Shrader CH, Borquez A, Vasylyeva TI, Chaillon A, Artamanova I, Harvey-Vera A, Vera CF, Rangel G, Strathdee SA, Skaathun B. 

AIDS Behav. 2023 Feb;27(2):484-495. doi: 10.1007/s10461-022-03783-6. Epub 2022 Aug 8. PMID: 35939177; PMCID: PMC9358371.


Experience delivering an integrated service model to people with criminal justice system involvement and housing insecurity. 

Baker O, Wellington C, Price CR, Tracey D, Powell L, Loffredo S, Moscariello S, Meyer JP. 

BMC Public Health. 2023 Feb 2;23(1):222. doi: 10.1186/s12889-023-15108-w. PMID: 36732685; PMCID: PMC9892679.


The effects of COVID-19 on New York State's Drug User Health Hubs and syringe service programs: a qualitative study. 

Ude M, Behrends CN, Kelly S, Schackman BR, Clear A, Goldberg R, Gelberg K, Kapadia SN. 

Harm Reduct J. 2023 Feb 2;20(1):12. doi: 10.1186/s12954-023-00742-9. PMID: 36732773; PMCID: PMC9893960.


Remote harm reduction services are key solutions to reduce the impact of COVID-19-like crises on people who use drugs: evidence from two independent structures in France and in the USA. 

Torres-Leguizamon M, Favaro J, Coello D, Reynaud EG, Néfau T, Duplessy C. 

Harm Reduct J. 2023 Jan 7;20(1):1. doi: 10.1186/s12954-023-00732-x. PMID: 36611167; PMCID: PMC9823260.


Care and Complexity in Emergency Housing: an Examination of the COVID-19 Shelter-in-Place (SIP) Hotel Program to House People Experiencing Homelessness in San Francisco. 

Abbs E, Schoenfeld N, Lai M, Satterwhite S, Zhou S, Bamberger J, Zevin B. 

J Urban Health. 2023 Jan 18. doi: 10.1007/s11524-022-00705-8. Epub ahead of print. PMID: 36652157.


Accessing needle exchange services in disasters for remote areas of Aotearoa New Zealand. 

Rijnink A, Blake D, Groot S, Brough C. 

Harm Reduct J. 2022 Dec 22;19(1):145. doi: 10.1186/s12954-022-00709-2. PMID: 36544156; PMCID: PMC9771773.


Health worker perceptions of the impact of COVID-19 on harm reduction services for people who inject drugs. 

Brener L, Horwitz R, Rance J, Caruana T, Bryant J. 

Health Soc Care Community. 2022 Nov;30(6):2320-2329. doi: 10.1111/hsc.13782. Epub 2022 Mar 16. PMID: 35293054; PMCID: PMC9111390.


Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire. 

Bolivar D, Hartung D, Silcox J, Bratberg J, Boggis J, Rabin M, Green TC. 

J Am Pharm Assoc (2003). 2022 Oct 15:S1544-3191(22)00357-0. doi: 10.1016/j.japh.2022.10.012. Epub ahead of print. PMID: 36369076; PMCID: PMC9574786.


Difficulty accessing supervised consumption services during the COVID-19 pandemic among people who use drugs in Vancouver, Canada. 

Cassie R, Hayashi K, DeBeck K, Milloy MJ, Cui Z, Strike C, West J, Kennedy MC. 

Harm Reduct J. 2022 Nov 18;19(1):126. doi: 10.1186/s12954-022-00712-7. PMID: 36401299; PMCID: PMC9675060.


Changes in supervised consumption site use and emergency interventions in Montréal, Canada in the first twelve months of the COVID-19 pandemic: An interrupted time series study. 

Zolopa C, Brothers TD, Leclerc P, Mary JF, Morissette C, Bruneau J, Hyshka E, Martin NK, Larney S. 

Int J Drug Policy. 2022 Oct 17;110:103894. doi: 10.1016/j.drugpo.2022.103894. Epub ahead of print. PMID: 36308892; PMCID: PMC9574459.


The impact of the COVID-19 pandemic on harm reduction services in Catalonia: the experience of people who use drugs and harm reduction professionals. 

Bosch-Arís M, Gasulla L, de Gispert T, Segura L, Colom J. 

Harm Reduct J. 2022 Oct 26;19(1):118. doi: 10.1186/s12954-022-00699-1. PMID: 36289531; PMCID: PMC9596343.


Supporting syringe services programs in the initiation and scale-up of vaccine administration: findings from in-depth interviews. 

Carry M, Bixler D, Weng MK, Doshani M, Roberts E, Montgomery MP. Supporting 

Harm Reduct J. 2022 Sep 1;19(1):100. doi: 10.1186/s12954-022-00681-x. PMID: 36050735; PMCID: PMC9435406.


Supporting Self-isolation for COVID-19 With "Risk Mitigation" Prescribing and Housing Supports for People Who Use Drugs: A Case Report. 

Hong RH, Brar R, Fairbairn N. 

J Addict Med. 2022 Sep-Oct 01;16(5):592-594. doi: 10.1097/ADM.0000000000000954. Epub 2022 Feb 10. PMID: 35149612; PMCID: PMC9531921.


Australien. Changes in the use of Melbourne’s Medically Supervised Injecting Room (MSIR) over the COVID-19 pandemic 

The Illicit Drug Reporting System (IDRS) is a national drug monitoring system intended to identify emerging trends of local and national concern in illicit drug markets, and form part of Drug Trends. 

Supervised injecting facilities (SIFs) have been shown to reduce overdose-related morbidity and mortality, drug-related risk behaviors, and to improve public amenity.  

In this bulletin, we update findings from a previous IDRS Bulletin that included information on the use of the North Richmond MSIR in 2019 to examine responses to the 2020 and 2021 IDRS surveys of people who inject drugs in order to examine any changes in MSIR use evident in the Melbourne IDRS samples over the COVID-19 pandemic. (UNSW, NDARC, Australien, August 2022)


Harm reduction and abstinence-based models for treatment of substance use disorders during the COVID-19 pandemic: a global perspective. 

Narasimha VL, Butner J, Hanafi E, Farokhnia M, Bhad R, Chalabianloo F, Kouimtsidis C, Baldacchino A, Arunogiri S. 

BJPsych Int. 2022 Aug;19(3):66-69. doi: 10.1192/bji.2022.1. PMID: 36287782; PMCID: PMC9540565.


Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: A mixed methods study of syringe services program perspectives. 

Austin EJ, Corcorran MA, Briggs ES, Frost MC, Behrends CN, Juarez AM, Frank ND, Healy E, Prohaska SM, LaKosky PA, Kapadia SN, Perlman DC, Schackman BR, Jarlais DCD, Williams EC, Glick SN. 

Int J Drug Policy. 2022 Nov;109:103825. doi: 10.1016/j.drugpo.2022.103825. Epub 2022 Aug 10. PMID: 35977459; PMCID: PMC9364718.


Time-series analysis of presentations to four syringe dispensing machines and a needle and syringe programme during COVID-19 lockdowns in Melbourne, Australia. 

O'Keefe D, Livingston M, Cossar RD, Kerr P, Jacka D, Dietze P. 

Harm Reduct J. 2022 Sep 7;19(1):101. doi: 10.1186/s12954-022-00683-9. PMID: 36071500; PMCID: PMC9449958.


COVID-19 and the opportunity for gender-responsive virtual and remote substance use treatment and harm reduction services. 

Perri M, Schmidt RA, Guta A, Kaminski N, Rudzinski K, Strike C. 

Int J Drug Policy. 2022 Aug 8;108:103815. doi: 10.1016/j.drugpo.2022.103815. Epub ahead of print. PMID: 35969920; PMCID: PMC9359504.


Disparities in naloxone prescriptions in a University Hospital during the COVID-19 pandemic. 

Chieh K, Patel I, Walter L, Li L. 

Harm Reduct J. 2022 Jul 26;19(1):84. doi: 10.1186/s12954-022-00667-9. PMID: 35883136; PMCID: PMC9321310.


Perceptions of Homeless Adults and Their Providers on Coping With the Impact of COVID-19 Pandemic on Mental Health, Substance Use, and Harm Reduction Services. 

Nyamathi AM, Gelberg L, Lee D, Arce N, Patten-Jones A, Yadav K, Goodwine M, Alikhani M, Yao M, Chang AH, Salem BE. 

Glob Qual Nurs Res. 2022 Jul 27;9:23333936221108712. doi: 10.1177/23333936221108712. PMID: 35912133; PMCID: PMC9335488.


The changing landscape of pharmaceutical alternatives to the unregulated drug supply during COVID-19. 

McCrae K, Glegg S, Goyer MÉ, Le Foll B, Brar R, Sutherland C, Fairbairn N. 

Harm Reduct J. 2022 Jul 14;19(1):77. doi: 10.1186/s12954-022-00657-x. PMID: 35836189; PMCID: PMC9281344.


Kanada. There has been a big spike in homeless deaths in Toronto and other cities. The reasons go beyond a toxic drug supply

The cost of living, a housing crisis and COVID are factors. “People who have been invisible to society forever also died invisibly.”(Toronto Star, Kanada, 14.07.2022)


A rapid assessment of take-home naloxone provision during COVID-19 in Europe

Rebecca McDonald, Desiree Eide, Katri Abel-Ollo, Lee Barnsdale, Ben Carter, Thomas Clausen, Ed Day, Francina Fonseca, Elin Holmén, Kirsten Horsburgh, Mike Kelleher, Martin Kåberg, Martin Ladenhauf, Andrew McAuley, Nicola Metrebian, Joanne Neale, Stephen Parkin, Kevin Ratcliffe, Chris Rintoul, Josie Smith, Viktorija Stifanoviciute, Marta Torrens, Henrik Thiesen, John Strang,

International Journal of Drug Policy, Available online 1 July 2022, 103787, doi.org/10.1016/j.drugpo.2022.103787


“COVID knocked me straight into the dirt”: perspectives from people experiencing homelessness on the impacts of the COVID-19 pandemic. 

Rodriguez, N.M., Martinez, R.G., Ziolkowski, R. et al.

BMC Public Health 22, 1327 (2022). https://doi.org/10.1186/s12889-022-13748-y


Factors associated with self-reported avoidance of harm reduction services during the COVID-19 pandemic by people who use drugs in five cities in the United States and Canada. 

Feder KA, Choi J, Schluth CG, Hayashi K, DeBeck K, Milloy MJ, Kirk GD, Mehta SH, Kipke M, Moore RD, Baum MK, Shoptaw S, Gorbach PM, Mustanski B, Javanbakht M, Siminski S, Genberg BL. 

Drug Alcohol Depend. 2022 Jun 24:109544. doi: 10.1016/j.drugalcdep.2022.109544. Epub ahead of print. PMID: 35779987; PMCID: PMC9225925.


"COVID just kind of opened a can of whoop-ass": The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. 

Glegg S, McCrae K, Kolla G, Touesnard N, Turnbull J, Brothers TD, Brar R, Sutherland C, Le Foll B, Sereda A, Goyer MÈ, Rai N, Bernstein S, Fairbairn N. 

Int J Drug Policy. 2022 Jun 6;106:103742. doi: 10.1016/j.drugpo.2022.103742. Epub ahead of print. PMID: 35679695; PMCID: PMC9170132.


Vaccination and Communicable Disease Testing Services' Integration Within a Syringe Services Program: A Program Brief. 

Heidari O, Meyer D, O'Conor KJ, Cargill V, Patch M, Farley JE. COVID-19 

J Assoc Nurses AIDS Care. 2022 May-Jun 01;33(3):348-352. doi: 10.1097/JNC.0000000000000322. Epub 2022 Jan 12. PMID: 35025822.